SEC Form 4

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or Section 30(n) of the investment Company Act of 1940							
1. Name and Address of Reporting Person [*] LYONS GARY A			2. Issuer Name and Ticker or Trading Symbol CYTORI THERAPEUTICS, INC. [CYTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
			, <u></u> ,	X Director 10% Owner						
(Last)	act) (Eirct) (Middlo)		3. Date of Earliest Transaction (Month/Day/Year) 06/15/2016	Officer (give title Other (specify below) below)						
	ROID									
(Otres et)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	СА	92121		X Form filed by One Reporting Person						
			_	Form filed by More than One Reporting Person						
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	06/15/2016		x		1,900	A	(2)	4,358	Ι	By Trust ⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exerc Expiration Da (Month/Day/N	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Subscription Rights (Right to Buy)	\$2.55	06/15/2016		x			1,900	05/26/2016	06/10/2016	See Footnote ⁽²⁾	1,900	\$0	0	I	By Trust
Warrants (Right to Buy)	\$3.06 ⁽³⁾	06/15/2016		x		950		06/15/2016	12/14/2018	Common Stock	950	(2)	950	I	By Trust ⁽¹⁾

Explanation of Responses:

1. The Reporting Person maintains indirect ownership of these securities in his capacity as sole trustee and beneficiary of The Gary A. Lyons Revocable Living Trust U/A, DTD 6/8/2102 (the "Trust"), including 2,458 shares previously reported as directly held that were transferred by the Reporting Person to the Trust.

2. The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company) to all holders of the Company's common stock. The subscription rights entitled each recipient thereof to purchase units ("Units"). Each Unit consists of one share of the Company's common stock and 0.5 of a warrant, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was \$2.55.

3. Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of \$3.06 from the date of issuance through December 14, 2018.

Jeremy Hayden, by Power of Attorney for Gary A. Lyons

** Signature of Reporting Person

Date

06/16/2016

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.